BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kish M, Chan K, Perry K, Ko YJ. A systematic review and network meta-analysis of adjuvant therapy for curatively resected biliary tract cancers. Curr Oncol 2020;27:e20-6. [PMID: 32218664 DOI: 10.3747/co.27.5465] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Marcus R, Ferri-Borgogno S, Hosein A, Foo WC, Ghosh B, Zhao J, Rajapakshe K, Brugarolas J, Maitra A, Gupta S. Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:5709. [PMID: 34830866 DOI: 10.3390/cancers13225709] [Reference Citation Analysis]
2 Messori A, Bartoli L, Trippoli S. Adjuvant treatments in biliary tract cancer: an analysis based on restricted mean survival time. Digestive and Liver Disease 2020;52:1208-9. [DOI: 10.1016/j.dld.2020.05.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Chen Y, Zhang B, Liu C, Cao Y, Lyu C, Qiu M. Clinical efficacy of adjuvant treatments for patients with resected biliary tract cancer: a systematic review and network meta-analysis. BMJ Open 2022;12:e051421. [PMID: 35440445 DOI: 10.1136/bmjopen-2021-051421] [Reference Citation Analysis]
4 Utuama O, Permuth JB, Dagne G, Sanchez-Anguiano A, Alman A, Kumar A, Denbo J, Kim R, Fleming JB, Anaya DA. Neoadjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma: A Propensity Score Survival Analysis Supporting Use in Patients with High-Risk Disease. Ann Surg Oncol 2021;28:1939-49. [PMID: 33415559 DOI: 10.1245/s10434-020-09478-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]